<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35197626</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>603</Volume><Issue>7899</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A.</ArticleTitle><Pagination><StartPage>124</StartPage><EndPage>130</EndPage><MedlinePgn>124-130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41586-022-04424-7</ELocationID><Abstract><AbstractText>A hallmark pathological feature of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is the depletion of RNA-binding protein TDP-43 from the nucleus of neurons in the brain and spinal cord<sup>1</sup>. A major function of TDP-43 is as a repressor of cryptic exon inclusion during RNA splicing<sup>2-4</sup>. Single nucleotide polymorphisms in UNC13A are among the strongest hits associated with FTD and ALS in human genome-wide association studies<sup>5,6</sup>, but how those variants increase risk for disease is unknown. Here we show that TDP-43 represses a cryptic exon-splicing event in UNC13A. Loss of TDP-43 from the nucleus in human brain, neuronal cell lines and motor neurons derived from induced pluripotent stem cells resulted in the inclusion of a cryptic exon in UNC13A mRNA and reduced UNC13A protein expression. The top variants associated with FTD or ALS risk in humans are located in the intron harbouring the cryptic exon, and we show that they increase UNC13A cryptic exon splicing in the face of TDP-43 dysfunction. Together, our data provide a direct functional link between one of the strongest genetic risk factors for FTD and ALS (UNC13A genetic variants), and loss of TDP-43 function.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ma</LastName><ForeName>X Rosa</ForeName><Initials>XR</Initials><Identifier Source="ORCID">0000-0001-8297-4279</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Prudencio</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4894-4858</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Koike</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5067-8579</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vatsavayai</LastName><ForeName>Sarat C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Garam</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5907-1127</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Interdepartmental Program, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harbinski</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briner</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4760-5037</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clem Jones Centre for Ageing Dementia Research (CJCADR), Queensland Brain Institute (QBI), The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Caitlin M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Caiwei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8076-1242</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>H Broder</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Beryl B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyatt</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurylo</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Georgiana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekhoubad</LastName><ForeName>Shila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallee</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekonnen</LastName><ForeName>Gemechu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganser</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biophysics, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubien</LastName><ForeName>Jack D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-1203-0445</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen-West</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickles</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1725-9866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-4153-8187</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-6544-066X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><Identifier Source="ORCID">0000-0001-7189-7917</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myong</LastName><ForeName>Sua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biophysics, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0001-7874-9482</Identifier><AffiliationInfo><Affiliation>Maze Therapeutics, South San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. petrucelli.leonard@mayo.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL, USA. petrucelli.leonard@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gitler</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0001-8603-1526</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. agitler@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS104437</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG063780</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 GM139268</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG057195</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS084974</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG064690</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS123743</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG071326</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS113636</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007231</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG063911</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS120992</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485548">UNC13B protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2022 Mar;603(7899):33-34</RefSource><PMID Version="1">35197585</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Med. 2022 Apr 8;3(4):226-227</RefSource><PMID Version="1">35590152</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Trends Genet. 2022 Sep;38(9):889-891</RefSource><PMID Version="1">35773026</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="N">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>A.D.G. is a scientific founder of Maze Therapeutics. X.R.M. served as a consultant for Maze Therapeutics. M.P. and L.P. serve as consultants for Target ALS. F.H., B.B.C., D.W.W., K.K., G.&#xa0;Miller, S.&#xa0;Mekhoubad, N.S. and E.G. are employees of Maze Therapeutics, which has filed a patent (63/171,522) on methods to modulate splicing of <i>UNC13A</i>.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35197626</ArticleId><ArticleId IdType="pmc">PMC8891019</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04424-7</ArticleId><ArticleId IdType="pii">10.1038/s41586-022-04424-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS&#x2013;FTD. Science. 2015;349:650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es MA, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat. Genet. 2009;41:1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, et al. C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis. Ann. Neurol. 2014;76:120&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4137231</ArticleId><ArticleId IdType="pubmed">24931836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum. Mol. Genet. 2010;19:46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A, et al. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138:813&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, et al. Cryptic exon incorporation occurs in Alzheimer&#x2019;s brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol. 2017;133:923&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, et al. Tdp-43 cryptic exons are highly variable between cell types. Mol. Neurodegener. 2017;12:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289002</ArticleId><ArticleId IdType="pubmed">28153034</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 2020;130:6080&#x2013;6092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, et al. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero-Garcia J, et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. eLife. 2016;5:e11752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801060</ArticleId><ArticleId IdType="pubmed">26829591</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YI, et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 2018;50:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5742080</ArticleId><ArticleId IdType="pubmed">29229983</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga A, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS ONE. 2012;7:e43120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3416794</ArticleId><ArticleId IdType="pubmed">22900096</ArticleId></ArticleIdList></Reference><Reference><Citation>Carithers LJ, et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv. Biobank. 2015;13:311&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675181</ArticleId><ArticleId IdType="pubmed">26484571</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213121</ArticleId><ArticleId IdType="pubmed">4858229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipstein N, et al. Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. J. Clin. Invest. 2017;127:1005&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5330740</ArticleId><ArticleId IdType="pubmed">28192369</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng L, Kaeser PS, Xu W, S&#xfc;dhof TC. RIM proteins activate vesicle priming by reversing autoinhibitory homodimerization of munc13. Neuron. 2011;69:317&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3063404</ArticleId><ArticleId IdType="pubmed">21262469</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin I, Rosenmund C, S&#xfc;dhof TC, Brose N. Munc13-1 is essential for fusion competence of glutamatergic synaptic vesicles. Nature. 1999;400:457&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440375</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hme MA, et al. Active zone scaffolds differentially accumulate Unc13 isoforms to tune Ca2+ channel-vesicle coupling. Nat. Neurosci. 2016;19:1311&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">27526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Placek K, et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2019;73:190&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251755</ArticleId><ArticleId IdType="pubmed">30368160</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, et al. Genome-wide analyses as part of the international FTLD&#x2013;TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathol. 2019;137:879&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6533145</ArticleId><ArticleId IdType="pubmed">30739198</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol. Neurodegener. 2014;9:38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4190282</ArticleId><ArticleId IdType="pubmed">25239657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidal-Taboada JM, et al. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. J. Neurol. 2015;262:2285&#x2013;2292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26162714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, et al. UNC13A variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. Neurol. Sci. 2019;40:2293&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pubmed">31201598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H, et al. The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis. Ann. Neurol. 2020;88:796&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol. Aging. 2012;33:630.e3&#x2013;630.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Auton A, et al. A global reference for human genetic variation. Nature. 2015;526:68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4750478</ArticleId><ArticleId IdType="pubmed">26432245</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal variants by statistical fine-mapping. Nat. Rev. Genet. 2018;19:491&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6050137</ArticleId><ArticleId IdType="pubmed">29844615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Chen-Plotkin AS. The post-GWAS era: from association to function. Am. J. Hum. Genet. 2018;102:717&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986732</ArticleId><ArticleId IdType="pubmed">29727686</ArticleId></ArticleIdList></Reference><Reference><Citation>Pruim RJ, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2011;26:2336&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935401</ArticleId><ArticleId IdType="pubmed">20634204</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Barreau A, Rohatgi R. Phase separation-deficient TDP43 remains functional in splicing. Nat. Commun. 2019;10:4890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814767</ArticleId><ArticleId IdType="pubmed">31653829</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, A.-L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature10.1038/s41586-022-04436-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, et al. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol. Aging. 2013;34:357.e1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483408</ArticleId><ArticleId IdType="pubmed">22921269</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report. Brain. 2019;142:1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Maury Y, et al. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat. Biotechnol. 2015;33:89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">25383599</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieri G, et al. LRRK2 modifies &#x3b1;-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019;137:961&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531417</ArticleId><ArticleId IdType="pubmed">30927072</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum. Mol. Genet. 2017;26:3421&#x2013;3431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5886204</ArticleId><ArticleId IdType="pubmed">28637276</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen KD, Brenner SE, Dudoit S. Biases in Illumina transcriptome sequencing caused by random hexamer priming. Nucleic Acids Res. 2010;38:e131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896536</ArticleId><ArticleId IdType="pubmed">20395217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, et al. Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137:27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Misregulation of human sortilin splicing leads to the generation of a nonfunctional progranulin receptor. Proc. Natl Acad. Sci. USA. 2012;109:21510&#x2013;21515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535614</ArticleId><ArticleId IdType="pubmed">23236149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallegger M, et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell. 2021;184:4680&#x2013;4696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445024</ArticleId><ArticleId IdType="pubmed">34380047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent WJ, et al. The Human Genome Browser at UCSC. Genome Res. 2002;12:996&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186604</ArticleId><ArticleId IdType="pubmed">12045153</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, et al. Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol. Cell. Proteomics. 2010;9:705&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860236</ArticleId><ArticleId IdType="pubmed">20047951</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>